Calyx and Invicro are now Perceptive
Independent review of trial event assessments by adjudication experts.
Proven expertise in delivering high-quality imaging data at a global scale.
With strengths in instrument engineering, signal processing, and pharmaceutical R&D, Perceptive Discovery consistently delivers successful imaging study designs and executions.
Effective RTSM, built on 30 years of experience, and connected to an ecosystem which includes eConsent and eCOA.
Highly established imaging centers for first-in-human and multicenter trials.
900+ agents radiolabeled and counting.
Supporting both malignant and non-malignant indications.
Experts in Alzheimer’s Disease, Parkinson’s Disease imaging and more.
Supporting over 85% of radiopharmaceutical companies.
Optimize preclinical and clinical trials in other areas and drug classifications.
Therapeutic and technical expertise in imaging modalities, protocol design, and acquisition.
Oncology imaging, RTSM, and clinical adjudication services.
Tackling unique rare disease trial supply, imaging and adjudication challenges.
We are here to serve science.
From discovery, through early to late-phase clinical development, to regulatory approval and post-market, you can count on Perceptive to be dependable, diligent, and driven in everything we do.
Perceptive Discovery bridges preclinical insights to early clinical success, ensuring rigorous scientific analysis and high-quality data to support innovation.
Providing the right-fit randomization & trial supply management solution for your trials, delivered by experts.
The right people, experience, and technology to drive clinical trial imaging success.
The incidence of Drug-Induced Interstitial Lung Disease (DI-ILD) in oncology treatments is increasing, particularly with the growing use of Antibody Drug Conjugates (ADCs). However, trial sponsors are finding that DI-ILD monitoring during clinical development is not a simple process, as regular assessment of patient symptoms, Pulmonary Function Tests, and high-resolution chest CT scans are needed to meet regulatory expectations. As a result, many oncology trial sponsors are turning to clinical adjudicators for independent review of suspected or manifested DI-ILD and other event assessments.
In this webinar, a panel of independent radiologists and oncology imaging and clinical adjudication experts will review the implications of ILD toxicity monitoring and how, by following best practices, sponsors as well as treating physicians can minimize variability, ensure consistency through objective event evaluations, and confidently assess these and other events to ensure patient safety and enable smarter decision-making.
Navigating Drug-induced Interstitial Lung Disease in ADC Trials April 8, 2025 10:00 am ET
